LATEST TRIALS

  • Lung Cancer, Melanoma, Thyroid Cancer
    Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies
  • Solide Tumores
    A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors”
  • Melanoma, Pancreatic Cancer, Solide Tumores
    A phase Ib/II open label, multicentre study of PDR001 in combination with MCS110 in patients with advanced malignancies

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen